Reduction in PSA messenger-RNA expression and clinical recurrence in patients with prostatic cancer undergoing neoadjuva
- PDF / 200,082 Bytes
- 7 Pages / 610 x 792 pts Page_size
- 93 Downloads / 202 Views
BioMed Central
Open Access
Research
Reduction in PSA messenger-RNA expression and clinical recurrence in patients with prostatic cancer undergoing neoadjuvant therapy before radical prostatectomy Marco Grasso*1, Caterina Lania2, Salvatore Blanco1, Marco Baruffi1 and Simone Mocellin3 Address: 1Department of Urology, Desio Hospital, via Mazzini, 1 - 20033 Desio, Milan, Italy, 2Department of Urology, San Raffaele Hospital, via Olgettina 60 - 20100 Milan, Italy and 3Department of Surgery, University of Padova, Padova, Italy Email: Marco Grasso* - [email protected]; Caterina Lania - [email protected]; Salvatore Blanco - [email protected]; Marco Baruffi - [email protected]; Simone Mocellin - [email protected] * Corresponding author
Published: 22 April 2004 Journal of Translational Medicine 2004, 2:13
Received: 30 December 2003 Accepted: 22 April 2004
This article is available from: http://www.translational-medicine.com/content/2/1/13 © 2004 Grasso et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
Prostatic Cancerqrt-PCRPSAneoadjuvant therapy
Abstract Background: We assessed the incidence of micro-metastases at surgical margins (SM) and pelvic lymph nodes (LN) in patients submitted to radical retropubic prostatectomy (RP) after neoadjuvant therapy (NT) or to RP alone. We compared traditional staging to molecular detection of PSA using Taqman-based quantitative real-time PCR (qrt-PCR) never used before for this purpose. Methods: 29 patients were assigned to NT plus RP (arm A) or RP alone (arm B). Pelvic LN were dissected for qrt-PCR analysis, together with right and left lateral SM. Results: 64,3% patients of arm B and 26.6% of arm A had evidence of PSA mRNA expression in LN and/or SM. 17,2% patients, all of arm B, had biochemical recurrence. Conclusions: Qrt-PCR may be more sensitive, compared to conventional histology, in identifying presence of viable prostate carcinoma cells in SM and LN. Gene expression of PSA in surgical periprostatic samples might be considered as a novel and reliable indicator of minimal residual disease after NT.
Background Prostatic carcinoma has an unpredictable clinical behavior. This cancer is widespread in males with 1/5 of men being affected throughout life. Every year 209,900 new cases are diagnosed in the USA. However, only 20% of them will lead to demise of the patient with an approximately 9-year reduction in expected survival. Thus, prostate cancer remains the second cause of oncologic death in males in Europe and in the USA [1].
Because of patient-to-patient heterogeneity in the clinical behavior of this disease, prognostic markers that may help tailor therapeutic strategies to individual clinical situations are continuously re-assessed. This frequent reassessment leads to modifications of clinical criteria utilized for the selection of therapeutic strategies
Data Loading...
